Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Even that season ending with a first-round loss to the Warriors couldn't put a damper on things—the beam was lit. How does a team with a good coach and a good young core get from there to here in just ...